BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36806958)

  • 1. Design and discovery of novel dipeptide boronic acid ester proteasome inhibitors, an oral slowly-released prodrug for the treatment of multiple myeloma.
    Wang X; Zhang W; Wen T; Miao H; Hu W; Liu H; Lei M; Zhu Y
    Eur J Med Chem; 2023 Mar; 250():115187. PubMed ID: 36806958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Shi J; Wang X; Hu S; Liu Z; Zhu Y
    Bioorg Med Chem; 2018 Aug; 26(14):3975-3981. PubMed ID: 29934218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
    Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
    Zhang W; Wang X; Zhang H; Wen T; Yang L; Miao H; Wang J; Liu H; Yang X; Lei M; Zhu Y
    Bioorg Med Chem; 2021 Jun; 40():116182. PubMed ID: 33971487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of novel four-membered-heterocycle constructed peptidyl proteasome inhibitors with improved metabolic stability for cancer treatment.
    Wang H; Wu Z; Cao Y; Gao L; Shao J; Zhao Y; Zhang J; Zhou Y; Wei G; Li J; Zhu H
    Bioorg Chem; 2023 Sep; 138():106626. PubMed ID: 37295239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.
    Momose I; Abe H; Watanabe T; Ohba S; Yamazaki K; Dan S; Yamori T; Masuda T; Nomoto A
    Cancer Sci; 2014 Dec; 105(12):1609-15. PubMed ID: 25251038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.
    Agyin JK; Santhamma B; Roy SS
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6455-8. PubMed ID: 24119559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.
    Zhang J; Han M; Ma X; Xu L; Cao J; Zhou Y; Li J; Liu T; Hu Y
    Chem Biol Drug Des; 2014 Nov; 84(5):497-504. PubMed ID: 24751157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
    Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
    Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
    Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
    Qin JM; Huang RZ; Yao GY; Liao ZX; Pan YM; Wang HS
    Eur J Med Chem; 2017 Jan; 126():259-269. PubMed ID: 27889629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urea-containing peptide boronic acids as potent proteasome inhibitors.
    Han LQ; Yuan X; Wu XY; Li RD; Xu B; Cheng Q; Liu ZM; Zhou TY; An HY; Wang X; Cheng TM; Ge ZM; Cui JR; Li RT
    Eur J Med Chem; 2017 Jan; 125():925-939. PubMed ID: 27769033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entinostat-Bortezomib Hybrids against Multiple Myeloma.
    Ferro A; Graikioti D; Gezer E; Athanassopoulos CM; Cuendet M
    Molecules; 2023 Feb; 28(3):. PubMed ID: 36771118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
    ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From Nature to Synthetic Compounds: Novel 1(N),2,3 Trisubstituted-5-oxopyrrolidines Targeting Multiple Myeloma Cells.
    Listro R; Malacrida A; Ambrosio FA; Rossino G; Di Giacomo M; Cavalloro V; Garbagnoli M; Linciano P; Rossi D; Cavaletti G; Costa G; Alcaro S; Miloso M; Collina S
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo.
    Ashley JD; Stefanick JF; Schroeder VA; Suckow MA; Kiziltepe T; Bilgicer B
    J Med Chem; 2014 Jun; 57(12):5282-92. PubMed ID: 24897555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
    Zhuang R; Gao L; Lv X; Xi J; Sheng L; Zhao Y; He R; Hu X; Shao Y; Pan X; Liu S; Huang W; Zhou Y; Li J; Zhang J
    Eur J Med Chem; 2017 Jan; 126():1056-1070. PubMed ID: 28027531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
    Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
    Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.